Hence, anti-PD1 treatment not only blocks inhibitory receptors but also can suppress tumor growth by directly regulating tumor cell metabolism via modulating mTOR activity and reducing the glucose exhaustion in TME, which promotes CD8+ cytotoxic T lymphocyte (CTL) functions, suggesting a very effective and promising advancement for therapies targeting both tumor immunity and TME. The gene discussed is CD8A; the disease is neoplasm.